Top Markets
#1 Islamic Coin Islamic Coin +152.28%
#2 Bitway Bitway +56.97%
#3 Starpower Starpower +37.21%
#4 Wrapped STX (Velar) Wrapped STX (Velar) +28.40%
#5 aelf aelf +26.23%
#6 SkyAI SkyAI +19.20%
#7 Pons Pons +15.91%
#8 Decred Decred +14.29%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +14.08%
#10 DAPPOS DAPPOS +13.91%
Coin of the day
Islamic Coin Islamic Coin
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
GenSight Biologics S.A. GenSight Biologics S.A.

GenSight Biologics S.A.

SIGHT
Classifica tra le azioni #29770
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on... GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.
Prezzo delle azioni
$0.12122506
Capitalizzazione di mercato
$19.76M
Variazione (1 giorno)
-2.29%
Variazione (1 anno)
-39.86%
Paese
FR
Scambia GenSight Biologics S.A. (SIGHT)

Categoria

Healthcare
Utile per GenSight Biologics S.A. (SIGHT)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di GenSight Biologics S.A., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di GenSight Biologics S.A. dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR